What is the typical dosing for Tesamorelin?

FDA-approved dosing. Common doses observed in research: 2 mg once daily. Duration: Indefinite for approved indication. Administration: Subcutaneous injection.

Growth Hormone

Tesamorelin

Also known as: Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

FDA Approved

Buy in shop

Tesamorelin from $100/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: Tesamorelin

Category: Growth Hormone
FDA Status: FDA Approved
Clinical Status: FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)
Administration: Subcutaneous injection
Typical Dose: 2 mg daily (F8: 1.28 mg daily)
Frequency: Once daily
Duration: Indefinite for approved indication

Also Known As

Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

Mechanism of Action

Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis.

Research Summary

FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients.

Trial Progress:FDA Approved

Pre

III

FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

2 mg daily (F8: 1.28 mg daily)

Range

1.28-2 mg daily

Frequency

Once daily

FDA-approved dose is 2 mg (original) or 1.28 mg (F8/Egrifta WR formulation). Inject subcutaneously in abdomen. F8 requires weekly reconstitution vs daily.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

FDA-approved dosing

Doses from Studies

2 mg once daily

FDA Approved Labeling - Prescribed dose ↗

Duration

Indefinite for approved indication

Administration

Subcutaneous injection

Timing & Administration

Best Time to Take

Before bed (fasted)

Once daily before bed

Food Recommendation

Take on empty stomach

Why This Timing?

FDA-approved GHRH analog works best on empty stomach, timed with natural GH release during sleep.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Injection site reactions (common)
●Joint pain
●Peripheral edema
●Pain in extremities
●Muscle pain
●Increased diabetes risk
●May elevate blood glucose
●Allergic reactions including anaphylaxis (rare)
●FDA approved for HIV lipodystrophy

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

Tesamorelin from $100/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Tesamorelin do?

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.

How does Tesamorelin work?

Is Tesamorelin FDA approved?

Yes, Tesamorelin is FDA approved. FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)

What are the side effects of Tesamorelin?

Reported side effects include: Injection site reactions (common), Joint pain, Peripheral edema, Pain in extremities, Muscle pain. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Tesamorelin?

Community-reported common dose: 2 mg daily (F8: 1.28 mg daily) (Once daily). Range: 1.28-2 mg daily. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Tesamorelin or used in similar applications.

Ipamorelin

Clinical Trials

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.

Growth Hormone

MK-677

Clinical Trials

An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.

Growth Hormone

CJC-1295 (No DAC)

Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.

Growth Hormone

GHRP-6

Clinical Trials

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.

Growth Hormone

GHRP-2

Clinical Trials

A synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.

Growth Hormone

Sermorelin

Preclinical

A truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.

Growth Hormone

How to Use Tesamorelin Tesamorelin Alternatives Compare with Similar Browse All Peptides

Want updates on Tesamorelin research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides